Table 1.
Demographic and baseline disease characteristics
| Osimertinib-relapsed (n = 45) | All-treated population (N = 91) | |
|---|---|---|
| Median age, years (minimum–maximum) | 65 (39–85) | 61 (36–85) |
| Sex | ||
| Female | 25 (56) | 52 (57) |
| Male | 20 (44) | 39 (43) |
| Race | ||
| Asian | 19 (42) | 65 (71) |
| White | 20 (44) | 20 (22) |
| Black | 2 (4) | 2 (2) |
| Multiple/not reported | 4 (9) | 4 (4) |
| ECOG PS | ||
| 0 | 12 (27) | 29 (32) |
| 1 | 33 (73) | 62 (68) |
| History of smoking | ||
| Yes | 20 (44) | 41 (45) |
| No | 25 (56) | 50 (55) |
| Median time from initial diagnosis to first dose, months (minimum–maximum) | 32 (5–98) | 24 (1–98) |
| Location of metastasesa | ||
| Lymph node | 18 (40) | 44 (48) |
| Bone | 19 (42) | 31 (34) |
| Brain | 13 (29) | 30 (33) |
| Liver | 8 (18) | 10 (11) |
| Adrenal gland | 4 (9) | 4 (4) |
| Other/not reported | 22 (49) | 47 (52) |
| Median prior lines of therapy (minimum–maximum) | 2 (1–4) | 2 (0–9) |
| EGFR primary mutation | ||
| Exon 19 deletion | 30 (67) | — |
| Exon 21 L858R | 14 (31) | — |
| Unknown | 1 (2) | — |
| Prior systemic therapy | 45 (100) | — |
| Platinum-based chemotherapyb | 7 (16) | 18 (20) |
| EGFR TKIa | ||
| 1st or 2nd generation | 33 (73) | 54 (59) |
| 3rd generation | 45 (100) | 53 (58) |
| Received as 1st line | 12 (27) | — |
| Received as 2nd line | 33 (73) | — |
| No prior therapy | 0 | 23 (25) |
Data are number of patients (%) unless otherwise noted.
aPatients could be counted in more than one category.
bSeven patients had limited platinum exposure (<two cycles) given before first EGFR TKI in the osimertinib-relapsed group.